Basing drug reimbursement on cost-effectiveness provides too little incentives for R&D. The reason for this is that … protection is too high to warrant reimbursement according to the cost-effectiveness decision rule. We show in a theoretical model …

unique reimbursement system, which results in significant differences in patients' access to biosimilars. The importance of …. The aim of this paper is to compare selected aspects of reimbursement and access to the EMA authorized biosimilar … database, the Polish reimbursement list published by the Polish Ministry of Health, and two French reimbursement databases …

unique reimbursement system, which results in significant differences in patients’ access to biosimilars. The importance of …. The aim of this paper is to compare selected aspects of reimbursement and access to the EMA authorized biosimilar … database, the Polish reimbursement list published by the Polish Ministry of Health, and two French reimbursement databases …